FIGURE 6.

Increased survival of allograft islet transplantation following SB216763 treatment. A, diabetogenic B6 recipients of C3H islets were injected daily with 100 μm SB216763 postoperatively. Interestingly, these islets had a 2-fold slower rejection time than untreated B6 recipients as demonstrated by prolonged euglycemia. p = 0.0056 (log rank test). B, diabetogenic B6 recipients of C3H islets, depleted of CD25⁺ cells prior to transplantation, were injected daily with 100 μm SB216763 postoperatively. Depletion of Treg cells resulted in the elimination of SB216763 effect. This demonstration of GSK-3β inhibition (GSKi) in an in vivo model hints at the powerful possibilities of potential Treg cell therapy in transplantation. p = 0.1616 (log rank test). Casp., caspase-3; Inh, inhibitor.